Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | RET C634F |
| Gene Variant Detail | |
| Relevant Treatment Approaches | RET Inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| RET C634F | medullary thyroid carcinoma | predicted - sensitive | RET Inhibitor | Sorafenib | Case Reports/Case Series | Actionable | In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634F (PMID: 20368568; NCT00390325). | 20368568 |
| RET C634F | malignant pheochromocytoma | predicted - sensitive | RET Inhibitor | Selpercatinib | Case Reports/Case Series | Actionable | In a Phase I/II trial (LIBRETTO-001), Retevmo (selpercatinib) treatment resulted in a partial response with treatment lasting 37 months in a patient with metastatic pheochromocytoma harboring germline RET C634F (PMID: 38661071; NCT03157128). | 38661071 |
| RET C634F | medullary thyroid carcinoma | sensitive | RET Inhibitor | Selpercatinib | FDA approved - On Companion Diagnostic | Actionable | In a Phase I/II trial (LIBRETTO-001) that supported FDA approval, Retevmo (selpercatinib) treatment resulted in an objective response rate (ORR) of 69% (38/55, 5 complete and 33 partial responses) in previously treated adult and pediatric patients of 12 years and older with medullary thyroid cancer harboring RET mutations as detected by an approved test, including RET C634F; ORR was 73% (64/88) in treatment naive patients (PMID: 32846061; NCT03157128). | detail... detail... 32846061 |